Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
NCT05621330Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Dec 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary immune thrombocytopenia (ITP) comparing QL0911 with Placebo (2 arms). Primary endpoint: Proportion of patients achieving durable platelet response at 24 weeks. Started Oct 2019; status: completed.
02
Drugs
QL0911
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05621330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621330.